Vision and History
Eutropics’ PraediCare Dx™-platform provides a biomarker technology for accelerating drug discovery and development. By aiding in the selection of patients who are likely to respond to treatments being tested, the platform can help to bring more effective drugs to the clinic at greater speed and at reduced cost.
PraediCare Dx™ is practiced under intellectual property held by Eutropics that protects our technology and allows for our entry into the commercial diagnostics market. The company has entered into collaborations with pharmaceutical companies and leading academic cancer centers in the U.S.A., U.K., and Canada to further develop the platform for helping guide patient treatment and improve outcomes.